Expanding Market Share of Blood Collection Tube Preparation Equipment

「Net sales of blood collection tube preparation systems and related systems for the cumulative first-quarter period amounted to ¥719,878 thousand, up 100.1% year on year.」

「Revenue from blood collection tube preparation systems and related systems for the fiscal year was ¥4,892.088 million, up 34.5% year on year. Domestic revenue was ¥4,446.008 million, up 37.3%, as planned sales projects for equipment and systems for large-scale facilities progressed smoothly.」

「Revenue from blood collection tube preparation systems and related systems for the interim accounting period was ¥1,099.141 million, down 4.6% year on year. Domestic revenue was ¥895.467 million, down 8.3%, because sales of equipment and systems for large-scale facilities were lower than in the same period of the previous year. Overseas revenue was ¥203.674 million, up 16.0%, as sales, mainly in Southeast Asia, exceeded the same period of the previous year.」

「Revenue from blood collection tube preparation systems and related systems for the fiscal year was ¥3,636.434 million, down 15.4% year on year. Domestic revenue was ¥3,237.325 million, down 21.9%, as many sales projects for equipment and systems for large-scale facilities were brought forward or postponed. Overseas revenue was ¥399.108 million, up 156.2%, as sales, mainly in Southeast Asia and China, recovered substantially on orders for large systems and other factors.」

「Revenue from blood collection tube preparation systems and related systems for the interim accounting period was ¥1,151.990 million, down 4.0% year on year. Domestic revenue was ¥976.445 million, down 12.0%, as some sales projects for equipment and systems for large-scale facilities had been brought forward into the previous fiscal year. Overseas revenue was ¥175.544 million, up 96.5%, as sales projects, mainly in Southeast Asia, remained firm.」

「Revenue from blood collection tube preparation systems and related systems for the fiscal year was ¥4,299.244 million, up 20.3% year on year. Domestic revenue was ¥4,143.454 million, up 25.9%, as sales projects for large systems and systems for large-scale facilities grew substantially, driven by enhanced optional functions for blood collection support systems and improved convenience through the use of cloud services.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative third quarter was ¥2,062.392 million, up 10.0% year on year. Domestic revenue was ¥1,957.242 million, up 14.8%, as sales projects progressed smoothly, particularly through the enhancement of large-system functionality and the provision of efficient solutions. Overseas revenue was ¥105.150 million, down 38.1%, as sales of both large and compact systems fell below the same period of the previous year due to the postponement of projects to China and other factors.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative second quarter was ¥1,199.526 million, up 15.6% year on year. Domestic revenue was ¥1,110.188 million, up 17.1%, due partly to the smooth progress of large-system sales projects in the second quarter. Overseas revenue was ¥89.337 million, down 0.2%; sales of compact and medium-sized systems exceeded the same period of the previous year, but sales projects for large systems declined.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative first quarter was ¥412.816 million, down 12.4% year on year. Although a certain number of projects is expected from the second quarter onward, the number of projects was low in both Japan and overseas during the first quarter. Domestic revenue was ¥388.332 million, down 7.0%, while overseas revenue was ¥24.484 million, down 54.4%, as sales projects for both compact and large systems shifted from the first quarter to the second quarter or later.」

「Revenue from blood collection tube preparation systems and related systems for the fiscal year was ¥3,573.728 million, down 5.8% year on year. Domestic revenue was ¥3,292.328 million, down 6.5%, due to a decline in large-scale projects from the previous fiscal year and the postponement of some projects' sales to the following fiscal year or later.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative third quarter was ¥1,874.769 million, down 8.3% year on year. Domestic revenue was ¥1,704.908 million, down 5.6%, due partly to a decline in large-scale projects from the same period of the previous year. Overseas revenue was ¥169.860 million, down 29.0%, due partly to a decline in projects amid intensifying competition with other companies.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative second quarter was ¥1,037.828 million, down 30.0% year on year. Domestic revenue was ¥948.351 million, down 25.6%, as the decline in large-scale projects outweighed an increase in medium-sized and small projects. Overseas revenue was ¥89.476 million, down 56.9%, amid a difficult market environment in which recovery from the impact of COVID-19 was delayed across all regions and competition with other companies intensified.」

「Against this backdrop, the Company continued to focus on sales activities for blood collection tube preparation systems and related systems that contribute to the stable and efficient operation of medical facilities, while broadening its equipment lineup and system range. It also continued to propose the introduction of specimen testing equipment and work to ensure a stable supply of consumables and other products. As a result, revenue for the cumulative first quarter was ¥1,786.155 million, down 11.3% year on year.」

「The Company has assembled a product lineup including the large BC・ROBO-8001RFID, featuring radio-frequency identification, the medium-sized BC・ROBO-900 blood collection tube preparation system, and the compact BC・ROBO7, and will seek to further expand its sales channels.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative third quarter was ¥2,044.583 million, up 25.0% year on year. Revenue in Japan was ¥1,805.185 million, up 31.6%, as sales recovered from the previous year's decline, when demand for replacement of large-scale systems was in a trough, and unit sales of small and medium-sized models increased substantially. Overseas revenue was ¥239.398 million, down 9.1%, as unit sales stagnated in the third quarter.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative second quarter was ¥1,482.242 million, up 50.9% year on year. As the same period of the previous year was in a trough in demand for replacement of large-scale systems, domestic revenue rose 57.3% to ¥1,274.853 million on a rebound. Overseas revenue was ¥207.389 million, up 20.9%, as some markets that had stagnated because of COVID-19 began to recover, and both domestic and overseas revenue exceeded the same period of the previous year.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative first quarter was ¥660.822 million, up 62.5% year on year. Sales had fallen sharply in the same period of the previous year because of fewer large-scale replacement projects and sales delays caused by COVID-19, but recovered to normal levels in the first quarter. Domestic revenue was ¥568.977 million, up 51.0%, and overseas revenue was ¥91.844 million, up 207.0%, with both exceeding the same period of the previous year.」

「Revenue from blood collection tube preparation systems and related systems for the fiscal year was ¥3,303.434 million, down 22.0% year on year.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative third quarter was ¥1,635.430 million, down 41.7% year on year. Domestic revenue was ¥1,372.014 million, down 45.3%, as large-scale replacement projects had run their course by the end of the previous fiscal year and replacement demand was in a trough. Overseas revenue was ¥263.415 million, down 10.7%, as many projects were forced to delay sales because of the impact of COVID-19.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative second quarter was ¥982.155 million, down 50.7% year on year. Domestic revenue was ¥810.653 million, down 55.7%, as large-scale replacement projects had run their course by the end of the previous fiscal year and the current fiscal year entered a trough in replacement demand. Overseas revenue was ¥171.501 million, up 5.1%, partly because progress was made on projects delayed by the impact of COVID-19.」

「Revenue from blood collection tube preparation systems and related systems for the cumulative first quarter was ¥406.625 million, down 56.2% year on year. Domestic revenue was ¥376.706 million, down 56.3%, as large-scale replacement projects had run their course and the fiscal year entered a trough in replacement demand. Overseas revenue was ¥29.919 million, down 54.0%, due partly to delays and interruptions in sales projects for various countries resulting from the impact of COVID-19.」

「Against this backdrop, the Company worked to promote high-function models of its core blood collection tube preparation systems, which enable safer and more accurate blood collection operations. It also actively pursued sales expansion of the compact BC・ROBO 7 for small and medium-sized medical facilities and the stable supply of consumables and other products. Revenue from blood collection tube preparation systems for the fiscal year was ¥4,233.448 million, up 11.3% year on year.」

「Revenue from blood collection tube preparation systems for the cumulative third quarter was ¥2,803.686 million, up 35.4% year on year. Domestic revenue was ¥2,508.740 million, up 57.6% year on year, due to the concentration of large-scale replacement projects. Overseas revenue was ¥294.945 million, down 38.3% year on year, reflecting the reversal of the concentration of sales projects to China in the same period of the previous year.」

「Revenue from blood collection tube preparation systems for the cumulative second quarter was ¥1,993.667 million, up 31.5% year on year. Domestic revenue was ¥1,830.427 million, up 59.0% year on year, as large-scale replacement projects, including orders received by the end of the previous fiscal year, were concentrated. Overseas revenue was ¥163.240 million, down 55.2% year on year, partly because sales projects to China were concentrated in the same period of the previous year and orders were delayed in the second quarter.」

「Sales of blood collection tube preparation equipment for the cumulative first quarter were ¥927.975 million, up 69.6% year on year. Domestic sales rose 99.6% to ¥862.913 million, partly because sales from large replacement projects ordered by the end of the previous fiscal year were recorded in the first quarter. Meanwhile, overseas sales declined 43.3% to ¥65.062 million, as sales projects for China had been concentrated in the same quarter of the previous year.」

「Sales of blood collection tube preparation equipment for the fiscal year were ¥3,803.127 million, up 7.9% from the previous fiscal year. Domestic sales rose 3.7% to ¥3,221.302 million, reflecting the steady capture of replacement demand at medical facilities. Overseas sales rose 39.7% to ¥581.824 million, driven by growth in sales to East and Southeast Asian markets.」

「Sales of blood collection tube preparation equipment for the cumulative third quarter were ¥2,070.217 million, up 3.1% year on year. Domestic sales declined 7.8% to ¥1,592.003 million, as sales in the third quarter accounting period were slightly below the prior-year level, while overseas sales rose 70.7% to ¥478.213 million, with sales to Asia, mainly China, remaining strong.」

「Sales of blood collection tube preparation equipment for the cumulative second quarter were ¥1,515.905 million, up 46.6% year on year. Domestic sales rose 27.1% to ¥1,151.468 million, driven by replacement demand for older models and the growing adoption of high-value-added systems using RFID. Overseas sales rose 184.3% to ¥364.436 million, as sales to Asia, mainly China, remained strong.」

「Sales of blood collection tube preparation equipment for the cumulative first quarter were ¥547.026 million, up 12.3% year on year. Domestic sales declined slightly to ¥432.300 million, down 2.0% year on year, while overseas sales rose 150.2% to ¥114.725 million, driven in part by increased sales of compact blood collection tube preparation equipment in China.」

「Although we introduced the latest model during the period to expand sales, unit sales struggled as we entered a lull in replacement demand. Domestic sales were ¥3,106.832 million, down 2.8% from the previous fiscal year, while overseas sales were ¥416.343 million, down 2.2%.」

「Sales of blood collection tube preparation equipment for the cumulative third quarter were ¥2,007.308 million, down 3.8% year on year. Domestic sales were ¥1,727.099 million, down 4.7% year on year, as there were fewer replacement projects for core models in the first half than in the same period of the previous year. Meanwhile, overseas sales were ¥280.208 million, up 2.1% year on year, as sales to emerging markets increased.」

「In the specimen testing equipment field, we also continued to focus on expanding sales of the latest GASTAT-700Model blood gas analyser.」

「We began sales of the BC・ROBO-8001RFID, the latest model of our core blood collection tube preparation equipment, equipped with a wide range of functions to support smoother blood collection operations.」

「Amid this operating environment, the Company worked to expand sales by offering a product lineup that meets the diverse needs of medical institutions, including by securing replacement demand for BC・ROBO-8000RFID, its main blood collection tube preparation system, and beginning sales of the GASTAT-700Model series of specimen testing systems, which feature enhanced remote maintenance functions.」

「We have focused on capturing replacement demand from existing users with BC・ROBO-8000RFID, our core model of blood collection tube preparation equipment, while expanding sales of high-value-added products that contribute to labor savings in blood collection and urine collection operations at medical facilities, including the UA・ROBO-2000RFID fully automated urine aliquoting system, RFID blood transfusion management and verification systems, and RFID urine specimen management systems,」

「We will continue to focus on selling our core blood collection tube preparation equipment and peripheral equipment, for which demand is expected to grow as electronic medical records and ordering systems become more widespread through the digitization of medical facility operations.」

「Against this operating backdrop, we steadily captured replacement demand from existing users with BC・ROBO-8000RFID, our core model of blood collection tube preparation equipment, while focusing on expanding sales of high-value-added products that contribute to labor savings in blood collection and urine collection operations at medical facilities, including the UA・ROBO-2000RFID fully automated urine aliquoting system, RFID blood transfusion management and verification systems, and RFID urine specimen management systems.」

「We focused on further expanding market share by increasing sales of the UA・ROBO-2000RFID fully automated urine aliquoting system, RFID blood transfusion management and verification systems, and RFID urine specimen management systems.」